INTRODUCTION
A role for immunological mechanisms in the pathogenesis of inflammatory bowel disease has been suspected for years, however, the nature of this involvement remains to be elucidated. The National Cooperative Crohn's Disease Study (1) showed no response to azathioprine therapy of 2 months' duration. In contrast, Present et al. (2) demonstrated that as many as 67% of patients with Crohn's disease received beneficial responses when placed on medical therapy employing 6-mercaptopurine (6-MP). They also noted that clinical responses may be delayed, requiring 3-6 months of therapy. Other clinical studies (3) (4) (5) have suggested that azathioprine may be useful as a maintenance treatment in Crohn's disease. The mechanisms by which 6-MP effected a beneficial response in these studies were unknown.
Previous studies by Campbell et al. (6, 7) showed that Crohn's disease and ulcerative colitis patients treated with azathioprine, which is metabolized in vivo to 6-MP, had a decrease in killer-cell (K-cell) activity. Shih et al. (8) have demonstrated a profound decrease in the activity of both K cells and natural killer cells (NK cells) in the peripheral blood of multiple sclerosis patients treated with azathioprine. More recently, Prince et al. (9) showed that renal transplant patients on long-term azathioprine therapy had similar decreases in K-ceU and NK-cell activity.
In this study, we have examined NK-cell cytotoxic activity in Crohn's disease patients on and off long-term 6-MP therapy to see if decreased activity occurs as in other patient groups. We have also evaluated another aspect of NK-cell activity, the ability to suppress lymphoblastoid B-cell (LB Bcell) antibody production (10) , to see if it is likewise decreased. In addition, IgG antitetanus antibody (IgG-Tet)-producing LB B cells were tested in 6-MP-treated and untreated Crohn's disease patients following in vivo booster immunization with tetanus toxoid. Our findings indicate that long-term 6-MP therapy in Crohn's disease decreases both NK-cell cytotoxic and NK-cell antibody suppression activity. LB B-cell antibody production after tetanus immunization was improved, perhaps because of decreased NK-cell suppressor activity.
M A T E R I A L S A N D M E T H O D S

Control and Patient Populations
Normal controls consisted of healthy normal volunteers, mostly students and employees at the UCLA Medical Center. Gastrointestinal disease controls consisted of outpatients attending the UCLA Gastroenterology Clinic with a variety of gastrointestinal inflammatory conditions: two idiopathic chronic gastritis, two gastric ulcer, two esophagitis, one chronic pancreatitis, and one acute enteritis. Systemic lupus erythematosus inflammatory controls were recruited from the Rheumatology Clinic at Harbor-UCLA Medical Center. Crohn's disease patients were recruited from among those attending the Gastroenterology Clinic at UCLA, from those patients referred by other physicians in Los Angeles, or from patients in Dr. Korelitz's practice in New York. Clinical characteristics of the patients are outlined in Table I . All patients on 6-MP therapy had been treated for more than 4 months. All patients receiving corticosteroid therapy were on stable every-morning dosages and had taken their medications prior to phlebotomy.
For control of assay systems, blood from the New York subjects (3 normals, 3 Crohn's not on 6-MP, 12 Crohn's on 6-MP) was collected the same day, maintained at 4°C while being flown to Los Angeles and was simultaneously tested at UCLA. Other normals, disease controls, and Crohn's disease patients were tested over a 15-month period at UCLA.
All subjects had received previous tetanus toxoid immunizations, but none had been immunized in the previous 12 months. All procedures performed with the normals, disease controls, and patients were approved by the UCLA Human Subject Protection Committee.
Materials
Purified tetanus toxoid was generously provided by Wyeth Laboratories (Marietta, PA). Rabbit antihuman IgG used in enzyme-linked immunosorbent assays (ELISA) was obtained from Sigma Laboratories (St. Louis, MO) and microtiter plates used in ELISA tests were obtained from Cooke (Alexandria, VA). Alpha interferon was a gift of HoffmanLaRoche and Genentech Inc. Pokeweed mitogen was obtained from Grand Island Biological Co.
Immunization
Normal individuals, disease controls, and patients were given an intramuscular booster immunization with absorbed tetanus-diphtheria toxoids (Lederle Laboratories). Blood samples were collected just before and 7 days after booster immunization.
Lymphocyte Preparation
Human mononuclear leukocytes were prepared by Ficoll-Hypaque density centrifugation of heparinized peripheral blood obtained from the various donors (11) . Samples transported from New York were kept at 4°C for approximately 12 hr before separating and testing. Samples were warmed to 37°C prior to Ficoll-Hypaque centrifugation. To control for effects of cold incubation on NK activity and LB B-cell antibody production, four normal specimens were separated while fresh and following overnight incubation at 4°C. NK cytotoxic activity at effector to target ratios of 25/1 in fresh (67 --27%) and incubated specimens (60 ---30%) was not significantly different (P > 0.2). IgG-Tet production by fresh (76 ×/+ 3.6 ng/culture) and cold incubated cells (62 ×/+ 4.3 ng/culture) showed similar results (P > 0.2).
Lymphocyte Cultures
Triplicate cultures containing peripheral blood lymphocytes (1.5 million cells) were initiated in a final volume of 1.5 ml in round-bottom culture tubes. The cultures were incubated at 37°C with 5% CO2 for 3 days in a medium consisting of RPMI 1640 buffered with NaHCO3 and supplemented with L-glutamine (I0 raM), gentamicin (0.05 mg/ml), and 15% heat-inactivated fetal calf serum.
Lymphoblastoid-Cell Suppression Cultures
LB B-cell suppression cultures were performed similarly to lymphocyte cultures except that alpha interferon (100 U/ml) was added to stimulate NK cell-mediated suppression (10).
ELISA Assays for Antibody Production
The solid-phase quantitative ELISA tests for IgG-Tet were performed in microtiter plates as previously described (12), substituting alkaline phosphatase-coupled antibody for radioiodinated antibody in the developing antibody step.
NK K-562 Cytotoxicity Assays
Cytotoxicity tests were performed by 51Cr release in standard 96-well V-shaped microplates (Cooke, Alexandria, VA), in a total volume of 200 ixl. K-562 tumor-cell targets were labeled with 200 ixCi of Na51Cr (New England Nuclear, Boston, MA) for 1 hr at 37°C and washed three times. Ten thousand target cells were used in each microtiter well. Effector-to-target ratios of 25/1 and I0/1 were used. After a 4-or 18-hr incubation period, 100 ixl of supernatant was collected and cytotoxicity was estimated from the released radioactivity according to the formula: [(test release-spontaneous release)/(80% of total label-spontaneous release)] x 100.
Statistical Analysis
Results of IgG-Tet production are expressed as the geometric mean ×/+ standard deviation (SD).
All other results are expressed as the arithmetic mean ---SD. The statistical significance of differences between groups was established using the Mann-Whitney U test. The variability of the response was evaluated by chi-square analysis of values lying outside the normal mean ---2 SD.
R E S U L T S
NK-CelI Activity Against K-562 Targets
Lymphocytes from both New York Crohn's disease patient groups and normal controls were tested simultaneously for their ability to mediate cytolysis of the standard NK target cell K-562 (Fig. I) . Seven of 12 patients from the New York group had sufficient numbers of lymphocytes after separation to test for NK-cell cytotoxicity. NK-cell activity at effector-to-target ratios of 25/1 was not significantly different (P > 0.2) in normals (N = 3; 62 -+ 6.2% cytotoxicity) and Crohn's patients not on 6-MP (N = 3; 60.3 +-7.4% cytotoxicity). Significant reductions (P < 0.01) in the levels of detectable NK-cell activity were observed in patients receiving 6-MP therapy (N = 7; 19.9 -12.6% cytotoxicity). These observations were extended during subsequent testing over a 15-month period at UCLA, using effector-to-target ratios of 25/1 in a standard 51Cr release assay (Fig. 2) . Normals (N = 32; 33 -13.7% cytotoxicity) and gastrointestinal disease controls (N = 5; 33 -+ 21% cytotoxicity) were not significantly different (P > 0.2). Crohn's disease patients not on 6-MP (N = 22; 25.5 +-15% cytotoxicity) had slightly decreased NK activity compared to normals (0.04 < P < 0.05) but not compared to disease controls (P > 0.2). More impressive were the decreases (P < 0.01) in NK-cell activity (N = 10; 10.7 ---10% cytotoxicity) in patients on 6-MP therapy compared to normals and Crohn's disease patients not on 6-MP. Effector-to-target ratios of 10/I showed similar results (data not shown). There was little correlation between NK-cell activity and corticosteroid dosage (Fig. 3) , with r = 0.15 (P > 0.2) for Crohn's patients both on and off 6-MP therapy.
NK-Cetl Suppression of Antibody Production
To determine whether the subsets of NK cells which are capable of suppressing LB B-ceU antibody production in vitro (10) were also affected by 6-MP therapy, simultaneous LB B cell-containing cultures were performed with the addition of interferon, a modulator which stimulates NK-cell suppression of antibody production. The results of these experiments are shown in Fig. 4 
LB B-Cell Generation
Normal individuals, gastrointestinal disease controis, systemic lupus erythematosus inflammatory controls, and Crohn's disease patients were booster immunized with tetanus toxoid. All normal individuals (N = 59) responded to the immunization with the production of antitetanus LB B-cell activity 7 days after immunization (Fig. 5 ). There was no apparent difference in IgG-Tet production in the three normal specimens maintained at 4°C while being flown from New York to Los Angeles (data not shown). Normal values ranged from 44 to 325 ng/culture, with a geometric mean of 110 ×/+ 1.6 ng/culture. Gastrointestinal disease controls (N = 7) responded to immunization, producing 92.8 ×/+ 3.2 ng/culture, a value not significantly different from normal (P > 0.2). Systemic lupus erythematosus inflammatory controls (N = 9) also responded to immunization, producing 86 ×/+ 2.6 ng/culture, again not significantly different from normal (P > 0.1). In contrast, Crohn's patients not on 6-MP (N = 25) had a markedly decreased IgG-Tet LB B-cell response (32.2 ×/+ 12.1 rig/culture), significantly less than normal (P < 0.002). Additional evaluation of the data revealed a wide variability of response in Crohn's patients not on 6-MP, with a range extending from 0 to 3200 ng/culture. Eighty-six percent of these patients were outside the normal mean -+ 2 SD (X 2 = 53, P < 0.01). To assess the effects of 6-MP on the ability of Crohn's disease patients to generate IgG-Tet LB B-cell responses, 16 patients on 6-MP therapy for more than 4 months were evaluated. The LB B-cell responses of these patients were increased (81.4 x/+ 2.8 ng/culture) compared to those of Crohn's patients not on 6-MP and were not significantly different from normal (P > 0.2). There was also a decrease in the variability of response, with only 36% of the patients lying outside the normal mean -+ 2 SD. The variability of response was still significantly increased compared to normal (X 2 = 13, P < 0.01) and resembled that of the gastrointestinal disease controls. There was no significant difference in the LB B-cell response of those patients receiving steroids and those not on steroid therapy (13) .
DISCUSSION
Previous investigations of the immunosuppressive effects of azathioprine (6-9) have shown that its major effects following long-term in vivo therapy are on NK-and K-cell cytotoxic lymphocytes. These cells are large granular lymphocytes which are quite similar phenotypically and, in fact, may be identical or overlapping populations which are cytotoxic by different mechanisms (14) . Initially Campbell et al. (6, 7) demonstrated that inflammatory bowel disease patients treated with azathioprine had decreased K-cell activity as measured in an antibody-dependent cytotoxicity (ADCC) assay. Shih et al. (8) extended the in vivo evaluation of the effect of azathioprine on immune functions by prospectively studying a group of multiple sclerosis patients who had been treated with similar doses of this drug. The results from this study demonstrated a selective and profound decrease in the peripheral blood activity of K and NK cells. Other parameters tested, i.e., the T-and B-cell numbers and the phytohemagglutinin (PHA) and concanavalin A (Con A) proliferative responses, were unaffected. This reduced K-and NK-cell activity was due to a depletion of circulating cells and was not due to a decrease in cell function. A temporal delay in the loss of K-and NK-cell activity was observed, with an initial decline seen at 1 month after the initiation of therapy, followed by a nadir at 4-5 months. Interestingly, this time course was similar to that of clinical improvement seen in Crohn's disease patients by Present et at. (2) . More recently, Prince et al. (9) compared the immunosuppressive effects of long-term azathioprine versus prednisone therapy in renal transplant patients. They demonstrated that azathioprine, and not prednisone, suppressed NK and ADCC activity. The NK activity of peripheral blood lymphocytes in our Crohn's disease patients was slightly decreased in comparison to that of normals but not that of gastrointestinal disease controls. Previous investigators have found both normal (15) and decreased (16, 17) levels of peripheral blood NK-cell cytotoxic activity in inflammatory bowel disease. Differences in methodology, as well as differing levels of disease activity, may explain this variation in NK-cell cytotoxic activity. Ginsberg et al. (16) tested NK cytotoxicity following overnight culture of lymphocytes, which results in the activation of normal NK-ceU cytotoxicity. Our patients as well as those of James et al. (15) had minimal disease activity in comparison to those in studies which demonstrated decreased NK cytotoxicity activity (16, 17) . We have demonstrated that decreased NK-cell cytotoxic activity as well as decreased NK-cell suppression of LB B-cell antibody production occurs in the peripheral blood of Crohn's disease patients on long-term 6-MP therapy. These antibody-suppressing cells in normals are stimulated by interferon, are subject to cold target competition by K-5~i2 cells, and express the Leu I l phenotype (10) . They may represent a subset of NK cells.
Although the NK activity against K-562 targets is normal or slightly decreased in Crohn's disease patients not on 6-MP, it is possible that a subset of NK cells directed against LB B cells is increased in Crohn's patients, contributing to their abnormal antibody responses to tetanus. A second possibility is that greater activity of NK cells is induced by immunization in Crohn's patients than in normals. These hypotheses are currently being pursued.
There was little correlation between corticosteroid dosage and NK cytotoxic activity. This confirms the lack of corticosteroid effect on NK-cell cytotoxicity seen by Prince et al. (9) .
The relationship of these findings to the clinical efficacy of 6 (24) have isolated mononuclear cells from colonic mucosa of inflammatory bowel disease patients which are cytotoxic for autologous colonic epithelial cells, possibly by a K-or NK-cell mechanism. Further studies of NK cells at the intestinal level in Crohn's patients are required to determine the existence of NK-cell cytotoxic or antibody suppression activity in this compartment and its relationship to the clinical efficacy of 6-MP therapy.
In a previous study, we demonstrated that many Crohn's disease patients have defects in their humoral immune system in that they fail to generate normal levels of IgG-Tet antibody-producing LB Bcell activity following in vivo immunization (13) . In addition, these patients failed to show increases in serum levels of tetanus toxoid-specific IgG antibody. The present study adds new findings to the abnormal LB B-cell responses to tetanus recently associated with Crohn's disease patients not on 6-MP therapy. 6-MP-treated Crohn's patients made a significant IgG-Tet LB B-cell response following immunization. In addition, the variability of the response was decreased, with fewer patients lying outside the normal range. This improved LB B-cell response to tetanus may be related to the decreased NK-cell suppressor activity seen in these patients.
These suppressor cells may represent a previously unrecognized lymphoid subpopulation which is sensitive to 6-MP therapy. Further prospective evaluations of these cells in inflammatory bowel disease patients will help to determine the sensitivity of these NK suppressor cells to 6-MP therapy as well as the relationship between improved humoral responsiveness and clinical efficacy.
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